Key result
This comprehensive review evaluates the efficacy and safety of bridging therapy with low-molecular-weight heparin versus antiplatelet therapy in patients undergoing noncardiac surgery after PCI.
Why the study?
Patients undergoing noncardiac surgery after PCI present a challenge in balancing the risk of thrombotic events against the risk of bleeding associated with antithrombotic therapy.
Does bridging therapy with low-molecular-weight heparin (LMWH) compared to antiplatelet therapy improve efficacy and safety outcomes in patients undergoing noncardiac surgery after percutaneous coronary intervention?
Does bridging therapy with low-molecular-weight heparin (LMWH) compared to antiplatelet therapy improve efficacy and safety outcomes in patients undergoing noncardiac surgery after percutaneous coronary intervention?
This review summarizes current evidence on LMWH bridging versus antiplatelet therapy for patients undergoing noncardiac surgery after PCI to guide clinical decision-making regarding thrombotic and bleeding risks.
Bridging LMWH post-PCI for NCS remains uncertain; leaves open need for RCTs to define optimal periprocedural strategy.
BACKGROUND: This review article discussed the use of bridging therapy with low-molecular-weight heparin (LMWH) in patients who undergo noncardiac surgery (NCS) after percutaneous coronary intervention (PCI). HYPOTHESES: Patients who undergo PCI are at an increased risk of thrombotic events due to their underlying cardiovascular disease. However, many of these patients may require NCS at some point in their lives, which poses a significant challenge for clinicians as they balance the risk of thrombotic events against the risk of bleeding associated with antithrombotic therapy. RESULTS: This review evaluates the current evidence on the use of bridging therapy with LMWH in patients undergoing NCS after PCI, focusing on outcomes related to the efficacy and safety of antithrombotic therapy. The article also discusses the limitations of the current evidence and highlights areas where further research is needed to optimize the management of antithrombotic therapy in this patient population. CONCLUSION: The goal of this review was to provide clinicians with a comprehensive summary of the available evidence to guide clinical decision-making and improve patient outcomes.
No takes yet. Share an insight, caveat, or question.
Iqbal et al. (2024) conducted a review in Patients undergoing noncardiac surgery after percutaneous coronary intervention. Bridging therapy with low-molecular-weight heparin (LMWH) vs. Antiplatelet therapy was evaluated on Efficacy and safety of antithrombotic therapy. This comprehensive review evaluates the efficacy and safety of bridging therapy with low-molecular-weight heparin versus antiplatelet therapy in patients undergoing noncardiac surgery after PCI.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: